DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Congenital Afibrinogenemia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

This report covers drugs of 4 companies currently in different phases of development.

The report provides Congenital afibrinogenemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Key Topics Covered

1. Introduction

1.1. Research Methodology

1.2. Research Scope

1.2.1. Analysis by Company

1.2.2. Analysis by Phase

1.2.3. By Molecule Type

1.2.4. By region

2. Disease Overview

2.1.1. Introduction

2.1.2. Classification

2.1.3. Symptoms

2.1.4. Causes

2.1.5. Diagnoses

2.1.6. Treatment

2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

5.2.1. Phase of Development

5.2.1.1. Introduction

5.2.1.1.1. Drug Profiling

Drug Name Generic Name Synonyms Company Collaborator Route of administration Target Mechanism of Action Technology Molecule type CAS Number Weight Chemical Formula IUPAC name ATC code

5.2.1.1.2. Strategic Developments

5.2.1.1.3. Clinical trials

5.2.1.1.4. Clinical trial results

5.2.1.1.5. Patents

5.2.1.1.6. Technology

5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar Graph)

5.3. By Molecule Type

5.4. Analysis by Region

6. Company Profiling

6.1. Grifols, S.A

6.1.1. Introduction

6.1.2. Financials

6.1.3. Products and Services

6.1.4. SWOT

6.2. Biotest AG

6.3. Octapharma

6.3.1. Introduction

6.3.2. Financials

6.3.3. Products and Services

6.3.4. SWOT

6.4. CSL

6.4.1. Introduction

6.4.2. Financials

6.4.3. Products and Services

6.4.4. SWOT

For more information about this report visit https://www.researchandmarkets.com/research/z7w5js/congenital?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005807/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD: EUROPE NORTH AMERICA

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 05:36 AM/DISC: 06/05/2018 05:36 AM

http://www.businesswire.com/news/home/20180605005807/en